二次性進行型多発性硬化症(SPMS)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Secondary Progressive Multiple Sclerosis (SPMS) Overview 7
Therapeutics Development 8
Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS) – Overview 8
Pipeline Products for Secondary Progressive Multiple Sclerosis (SPMS) – Comparative Analysis 9
Secondary Progressive Multiple Sclerosis (SPMS) – Therapeutics under Development by Companies 10
Secondary Progressive Multiple Sclerosis (SPMS) – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Secondary Progressive Multiple Sclerosis (SPMS) – Products under Development by Companies 15
Secondary Progressive Multiple Sclerosis (SPMS) – Companies Involved in Therapeutics Development 16
AB Science 16
Biogen Idec Inc. 17
Daval International Ltd. 18
Genzyme Corporation 19
Glialogix, Inc. 20
Immune Response BioPharma, Inc. 21
Innate Therapeutics Limited 22
Kyorin Pharmaceutical Co., Ltd. 23
MedDay 24
Novartis AG 25
Opexa Therapeutics, Inc. 26
Secondary Progressive Multiple Sclerosis (SPMS) – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
Aimspro – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
BIIB-033 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
DC-TAB – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
GLX-1112 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
GZ-402668 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ibudilast – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
imilecleucel-t – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
interferon beta-1b – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
IR-902 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
masitinib – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
MD-1003 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
MIS-416 – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
natalizumab – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
siponimod – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecules for Multiple Sclerosis – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Secondary Progressive Multiple Sclerosis (SPMS) – Recent Pipeline Updates 61
Secondary Progressive Multiple Sclerosis (SPMS) – Discontinued Products 78
Secondary Progressive Multiple Sclerosis (SPMS) – Product Development Milestones 79
Featured News & Press Releases 79
Oct 07, 2014: Update on Innate’s Phase 2B trial and other recent activities 79
Aug 19, 2014: Innate’s Phase 2B clinical trial on SPMS to start recruiting patients following Perth site obtaining ethics approval 79
Jun 20, 2014: Update on Phase 2B Trial of MIS416 in Patients with Secondary Progressive Multiple Sclerosis 80
Jun 18, 2014: Compassionate Use Programme Update 80
May 13, 2014: Opexa Reaches Enrollment Target in Phase IIb Trial of Personalized Immunotherapy for Secondary Progressive Multiple Sclerosis 81
Apr 15, 2014: Innate Immunotherapeutics confirms Phase 2B trial on track and on budget 82
Mar 11, 2014: Innate Immunotherapeutics receives EU patent protection for use of MIS416 to treat or prevent radiation injury 83
Feb 03, 2014: Dr Larry Steinman, renowned multiple sclerosis specialist at Stanford University, endorses newly published MIS416 therapy validation in animal studies 83
Dec 16, 2013: Opexa Therapeutics Provides MS Trial Enrollment Update; 70% of Patients Enrolled 84
Nov 13, 2012: Opexa Receives Clinical Trial Approval From Health Canada For New T-Cell Therapy, Tcelna 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87